Objective: Outcome prediction of pT3 urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC) remains challenging. The objective of our study was to determine high-risk patients with poor survival outcome in a heterogeneous group substaged pT3 who might profit from early adjuvant chemotherapy. Materials and Methods: We compiled clinicopathological and immunohistochemical data of E-cadherin (E-cad) expression in 116 patients with pT3 UCB after RC in our single-center series. Multivariable Cox regression models including substaged pT3 established clinicopathological features, and the expression of the predictive immunohistochemical feature E-cad was used to identify independent predictors on progression-free (PFS), cancer-specific (CSS) and overall survival (OS), respectively. Results: No significant differences were found addressing clinicopathological data and substaged pT3. In multivariable Cox regression models, lymph node involvement was an independent predictor for PFS (p < 0.001), CSS (p < 0.001) and OS (p = 0.002), respectively. Lymphovascular invasion (LVI) significantly influenced PFS (p = 0.016). ASA score 3/4 independently predicted CSS (p = 0.049) and OS (p = 0.032). Neither pT3 substages nor E-cad expression were significant prognosticators for survival. Conclusions: In pT3 UCB patients with ASA 3/4, positive lymph node status and/or presence of LVI, administration of chemotherapy should be considered due to the high risk of poor oncological outcome. The immunohistochemical marker E-cad was not an independent predictor.

Keywords:
Bladder carcinoma, E-cadherin, Pathological stage T3, Pathology, Prognostic factors, Radical cystectomy
1.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:227-300.
2.
Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, National Cancer Institute, 2012.
3.
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology (EAU): Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-1018.
4.
Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual, ed 6. Philadelphia, Lippincott-Raven, 2002.
5.
Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG: Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol 2004;171:640-645.
6.
Bastian PJ, Hutterer GC, Shariat SF, Rogers CG, Palapattu GS, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI; Bladder Cancer Research Consortium: Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int 2008;101:450-454.
7.
Boudreaux KJ Jr, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA Jr, Clark PE: Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer 2009;115:770-775.
8.
Dincel C, Kara C, Balci U, Ozer K, Ozbir S, Sefik E, Gorgel SN, Girgin C: Comparison of microscopic (pT3a) and gross extravesical extension (pT3b) in pathological staging of bladder cancer: analysis of patient outcomes. Int Urol Nephrol 2013;45:387-393.
9.
Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Stief CG, Reich O, Shariat SF: pT3 substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol 2010;184:470-474.
10.
Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF: Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 2011;185:1216-1221.
11.
May M, Bastian PJ, Brookman-May S, Fritsche HM, Bolenz C, Gilfrich C, Otto W, Trojan L, Herrmann E, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M: External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder. J Urol 2012;187:1210-1214.
12.
Jeanes A, Gottardi CJ, Yap AS: Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-6929.
13.
Kashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T: The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007;14:789-794.
14.
Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI: Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005;23:6533-6539.
15.
Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, Shariat SF: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012;61:854-855.
16.
Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-2422.
17.
Buscarini M, Josephson DY, Stein JP: Lymphadenectomy in bladder cancer: a review. Urol Int 2007;79:191-199.
18.
Rabbani F, Lee C, Chang SS, Lerner SP, Wood DP, Herr HW: Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stage. Urol Int 2010;84:14-22.
19.
Novara G, Ficarra V, Alrabi N, Dalpiaz O, Martignoni G, Galfano A, Cavalleri S, Artibani W: Prognostic factors in a recent series of patients treated with radical cystectomy for bladder cancer. Urol Int 2005;75:10-16.
20.
Fritsche HM, May M, Denzinger S, Otto W, Siegert S, Giedl C, Giedl J, Eder F, Agaimy A, Novotny V, Wirth M, Stief C, Brookman-May S, Hofstädter F, Gierth M, Aziz A, Kocot A, Riedmiller H, Bastian PJ, Toma M, Wieland WF, Hartmann A, Burger M: Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol 2013;63:739-744.
21.
May M, Herrmann E, Bolenz C, Tiemann A, Brookman-May S, Fritsche HM, Burger M, Buchner A, Gratzke C, Wülfing C, Trojan L, Ellinger J, Tilki D, Gilfrich C, Höfner T, Roigas J, Zacharias M, Gunia S, Wieland WF, Hohenfellner M, Michel MS, Haferkamp A, Müller SC, Stief CG, Bastian PJ: Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol 2011;59:712-718.
22.
Gierth M, Fritsche HM, Buchner H, May M, Aziz A, Otto W, Bolenz C, Trojan L, Hermann E, Tiemann A, Müller SC, Ellinger J, Brookman-May S, Stief CG, Tilki D, Nuhn P, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Wieland WF, Riedmiller H, Denzinger S, Bastian PJ, Burger M: Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. World J Urol 2014;32:365-371.
23.
Mayr R, May M, Martini T, Lodde M, Comploj E, Pycha A, Strobel J, Denzinger S, Otto W, Wieland W, Burger M, Fritsche HM: Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662-670.
24.
Morton RA Jr, Ewing CM, Watkins JJ, Isaacs WB: The E-cadherin cell-cell adhesion pathway in urologic malignancies. World J Urol 1995;13:364-368.
25.
Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA Jr, Wheeler TM, Lerner SP: E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001;165:1473-1479.
26.
Lipponen PK, Eskelinen MJ: Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 1995;121:303-308.
27.
Mialhe A, Louis J, Montlevier S, Peoch M, Pasquier D, Bosson JL, Rambeaud JJ, Seigneurin D: Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 1997;17:124-137.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.